New office and new leader aim to streamline FDA cancer drug review process.
作者信息
Twombly Renee
出版信息
J Natl Cancer Inst. 2005 May 18;97(10):708-9. doi: 10.1093/jnci/97.10.708.
PMID:15900036
Abstract
摘要
相似文献
1
New office and new leader aim to streamline FDA cancer drug review process.
J Natl Cancer Inst. 2005 May 18;97(10):708-9. doi: 10.1093/jnci/97.10.708.
2
Can single-patient investigational new drug studies hurry slow trains to the fast track?
Drug Discov Today. 2006 Mar;11(5-6):185-6. doi: 10.1016/S1359-6446(05)03707-4.
3
How are drugs approved? Part 3. The stages of drug development.
J Psychosoc Nurs Ment Health Serv. 2008 Mar;46(3):17-20.
4
Japan works to shorten "drug lag," boost trials of new drugs.
J Natl Cancer Inst. 2010 Feb 3;102(3):148-51. doi: 10.1093/jnci/djq017. Epub 2010 Jan 27.
5
The FDA's new oncology office.
Clin Adv Hematol Oncol. 2005 Aug;3(8):612-3.
6
FDA not NIH can speed new drugs.
Nature. 2011 Apr 14;472(7342):169. doi: 10.1038/472169a.
7
Oncology's first Phase 0 trial.
J Natl Cancer Inst. 2009 Jul 15;101(14):978-9. doi: 10.1093/jnci/djp213. Epub 2009 Jul 7.
8
From laboratory to medicine cabinet.
Caring. 1992 Nov;11(11):16-20.
9
The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
Oncologist. 2010;15 Suppl 1:13-8. doi: 10.1634/theoncologist.2010-S1-13.
10
Changes in FDA drug classification and priority review policy.
Am J Hosp Pharm. 1992 Oct;49(10):2383, 2386.
Zotero 插件